Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared a post on X:
“A study finds no difference in pCR between regimens with or without anthracyclines in HER2-positive inflammatory breast cancer (IBC). But those on anthracyclines had better disease control. More research needed.”
Title: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study
Authors: Toshiaki Iwase, Nithya Sridhar, Megumi Kai, Wenli Dong, Yu Shen, Savitri Krishnamurthy, Anthony Lucci, H. T. Carisa Le-Petross, Azadeh Nasrazadani, Sadia Saleem, Rachel M. Layman, Vincente Valero, Debasish Tripathy, Wendy A. Woodward, Yee Chung Cheng, Faina Nakhlis, Jenifer R. Bellon, Filipa Lynce, Naoto T. Ueno
Read the Full Article.
More posts featuring Naoto T Ueno.
